J Endod:MTA/聚已内酯3维支架材料促进组织再生的成骨特性研究

2017-04-18 lishiting MedSci原创

这篇研究的目的是为了评估MTA/聚已内酯(MTA/PCL)混合3维(3D)支架材料是否可以为人牙髓细胞(hDPCs)的成骨分化提供适宜的微环境,并进一步研究MTA/PCL复合物对混合支架材料生物活动的影响。

这篇研究的目的是为了评估MTA/聚已内酯(MTA/PCL)混合3维(3D)支架材料是否可以为人牙髓细胞(hDPCs)的成骨分化提供适宜的微环境,并进一步研究MTA/PCL复合物对混合支架材料生物活动的影响。

研究是将MTA悬浮于乙醇溶液中并缓慢滴入PCL内,通过可打印的MTA基质材料生成MTA/PCL复合物。随后,将MTA/PCL复合物融入高度均匀的支架材料内,并通过3D打印技术控制材料孔洞的大小和结构。支架材料的机械性能和磷灰石沉淀以及材料对细胞活性的影响通过在材料上培养hDPCs进行评估。

结果显示,MTA/PCL支架材料拥有均匀、高孔隙率的(70%),直径为450-μm的孔洞,并且抗压强度可达到4.5 MPa。除此之外,MTA/PCL支架材料可以明显促进hDPCs的粘附、增殖和分化。

结论:3D打印MTA/PCL支架材料不仅拥有优良的理化特性,而且可以增强hDPCs的成骨分化能力。研究的所有结果都支持一种观点:MTA/PCL多孔支架材料作为一种新型生物材料应用于骨组织工程的价值可观。

原始出处:

Chiu YC, Fang HY, et al. The Characteristics of Mineral Trioxide Aggregate/Polycaprolactone 3-dimensional Scaffold with Osteogenesis Properties for Tissue Regeneration. J Endod. 2017 Apr 4. pii: S0099-2399(17)30014-6. doi: 10.1016/j.joen.2017.01.009.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775791, encodeId=617f1e7579147, content=<a href='/topic/show?id=a7235e107b2' target=_blank style='color:#2F92EE;'>#支架材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57107, encryptionId=a7235e107b2, topicName=支架材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce4f38811844, createdName=tidiq, createdTime=Fri Jun 02 03:52:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351600, encodeId=a934135160033, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368023, encodeId=8b991368023e6, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591981, encodeId=21031591981e2, content=<a href='/topic/show?id=595ce765983' target=_blank style='color:#2F92EE;'>#组织再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77659, encryptionId=595ce765983, topicName=组织再生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11e818060478, createdName=sunyl13, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775791, encodeId=617f1e7579147, content=<a href='/topic/show?id=a7235e107b2' target=_blank style='color:#2F92EE;'>#支架材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57107, encryptionId=a7235e107b2, topicName=支架材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce4f38811844, createdName=tidiq, createdTime=Fri Jun 02 03:52:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351600, encodeId=a934135160033, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368023, encodeId=8b991368023e6, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591981, encodeId=21031591981e2, content=<a href='/topic/show?id=595ce765983' target=_blank style='color:#2F92EE;'>#组织再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77659, encryptionId=595ce765983, topicName=组织再生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11e818060478, createdName=sunyl13, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=)]
    2017-04-20 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775791, encodeId=617f1e7579147, content=<a href='/topic/show?id=a7235e107b2' target=_blank style='color:#2F92EE;'>#支架材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57107, encryptionId=a7235e107b2, topicName=支架材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce4f38811844, createdName=tidiq, createdTime=Fri Jun 02 03:52:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351600, encodeId=a934135160033, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368023, encodeId=8b991368023e6, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591981, encodeId=21031591981e2, content=<a href='/topic/show?id=595ce765983' target=_blank style='color:#2F92EE;'>#组织再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77659, encryptionId=595ce765983, topicName=组织再生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11e818060478, createdName=sunyl13, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=)]
    2017-04-20 liuxiaona
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775791, encodeId=617f1e7579147, content=<a href='/topic/show?id=a7235e107b2' target=_blank style='color:#2F92EE;'>#支架材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57107, encryptionId=a7235e107b2, topicName=支架材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce4f38811844, createdName=tidiq, createdTime=Fri Jun 02 03:52:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351600, encodeId=a934135160033, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368023, encodeId=8b991368023e6, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591981, encodeId=21031591981e2, content=<a href='/topic/show?id=595ce765983' target=_blank style='color:#2F92EE;'>#组织再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77659, encryptionId=595ce765983, topicName=组织再生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11e818060478, createdName=sunyl13, createdTime=Thu Apr 20 10:52:00 CST 2017, time=2017-04-20, status=1, ipAttribution=)]

相关资讯

2017 EBMT:如何选择异基因造血干细胞移植的更佳供者----半相合移植的供者选择

2017年3月26日—29日,第43届欧洲血液和骨髓移植学会年会(EBMT 2017)在法国马赛如期举行。在这一全球性高级别的科学盛会上,北京大学血液病研究所所长黄晓军教授应邀做了“How to choose the Best Donor for Allogeneic Stem Cell Transplatation”的大会报告。

Cell Stem Cell:北大学者首次实现了单细胞水平的5-醛基胞嘧啶全基因组测序

来自北京大学生命科学学院,BIOPIC中心的研究人员发表了题为“Single-Cell 5-Formylcytosine Landscapes of Mammalian Early Embryos and ESCs at Single-Base Resolution”的文章,在国际上首次实现了单细胞水平的5-醛基胞嘧啶全基因组测序,并解析了小鼠着床前胚胎中的单碱基分辨率5-醛基胞嘧啶(5fC)谱图

EMBO Journal:脂类代谢调控干细胞多能性的新机制

2017年4月4日,国际知名学术期刊《EMBO Reports》杂志上在线发表了中国科学技术大学生命科学学院高平课题组与张华凤课题组题为“Fatty acid synthesis is critical for stem cellpluripotency via promoting mitochondrial fission”的研究论文。2017年4月4日,国际知名学术期刊《EMBO Report

Cell Death Dis:肺转移性乳腺癌干细胞被发现

中科院上海生科院人口健康领域胡国宏研究组研究鉴定出了一个具有肺转移能力的乳腺癌干细胞亚群,并揭示其在乳腺癌转移中的作用机制。相关研究成果已在线发表于《细胞死亡与疾病》。

细胞治疗技术迎来医学新浪潮,生物谷十年聚焦产业发展

2016年4月,震动全世界的魏则西事件,除了让百度、莆田系、部队医院等成为众矢之的,也将癌症免疫细胞治疗的乱象曝光于众。同年5月初,国家卫计委重申,要求进一步加强对违规医疗行为的监管和打击力度,并紧急叫停细胞免疫治疗临床应用。这是继2015年6月29日国家卫生计生委对准入审批调整后的又一次变局。自此,已在全国多家医院商业性应用并收费的免疫疗法,纷纷踩下刹车。但时隔一年,今年3月,国家卫计委强调,免

Stem Cell Rep:培养皿中培育出脑组织

人体中最复杂的器官是大脑。由于其复杂性,当然,也出于道德原因,对其进行科学实验例如可以帮助我们了解帕金森病等神经变性疾病的实验是非常困难的。